(HealthDay News) — For patients with high-risk prostate cancer, testosterone recovery is shorter for patients receiving 18 months vs. 36 months of androgen deprivation therapy (ADT), and is associated with improved quality of life, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from September 14–18 in San Francisco.

Abdenour Nabid, MD, from the University Hospital Centre of Sherbrooke in Canada, and colleagues examined quality of life after testosterone recovery in a multicenter randomized trial comparing 18 months ADT with 36 months ADT. Quality of life was assessed using the validated EORTC30 and PR25 tools, which included 55 items that were grouped in 21 scales.

The researchers found that with an 84-month median follow-up, 50.9%  of patients recovered normal testosterone levels (55.7% in 18-month ADT vs. 44.9% in 36-month ADT; P=0.01). The median time to testosterone recovery was shorter in the 18 vs. 36-month ADT group (47.2 vs. 73.2 months; P<0.001). Patients with testosterone recovery had better quality of life, with significant differences in 26/55 items and 12/21 scales. Five of the 26 items and one of 12 scales were clinically relevant.

“The results of the analysis are not surprising considering the side effects of ADT, and that testosterone recovery has significant impact on patients’ improved quality of life,” Nabid said in a statement.

One author disclosed financial ties to pharmaceutical companies, including AstraZeneca, which funded the study.

Press Release
More Information